HD-PLC-ALLIANCE
16.3.2021 07:02:09 CET | Business Wire | Press release
In order to integrate the latest improvements in speed and range of the HD-PLC*1 technology promoted by HD-PLC Alliance*2 , the Alliance has proposed the specifications of the next generation technology to the IEEE Standards Association*3 . To the great satisfaction of the Alliance members, recently published IEEE 1901-2020 Standard includes the latest HD-PLC features that provide higher speed, longer range wired communications over existing metal wires (control cable, coaxial cable, power cable, etc.).
Compared with wireless communication systems, HD-PLC enables more secure, stable and reliable communications. Furthermore, the use of existing cables allows a network infrastructure to cover not only indoors such as homes, buildings and factories but also outdoors extending several kilometers.
Mr. Yoshiyuki Miyabe, Senior Adviser of HD-PLC Alliance and Senior Managing Executive Officer of Panasonic Corporation, has sent a message, “Our company and HD-PLC Alliance have developed the HD-PLC technology cooperatively, which is now published as IEEE 1901-2020 standard. We anticipate this standardization will help make HD-PLC a breakthrough technology for the coming era of IoT. Making the most of this result for various products and business solutions for the future, we endeavor to further support innovation and advancement of the technology to provide new values to our customers.”
HD-PLC Alliance devotes its efforts to promote the technology through a certification program and logo. The test environment is being updated to offer the current third-generation communication compatibility services as well as upcoming fourth generation interoperability certification services compliant with IEEE 1901-2020.
On March 18, 2021, a webinar*4 on this technology will be held, organized by IEEE SA and HD-PLC Alliance. Also, please visit our renewed website.*5
Related Information:
HD-PLC Alliance members Press Release
[Panasonic Corporation]
Licensing IP Core for Semiconductors Complying with the IEEE 1901–2020 International Standard
https://news.panasonic.com/global/press/data/2021/03/en210316-2/en210316-2.html
[Socionext Inc.]
Socionext Agrees With MIRAIT, MMD, And Nuri Telecom On Next-Generation Long-Distance Power Line Communications For Verification And Social Implementation
https://www.socionext.com/en/pr/sn_pr20210309_01e.pdf
(Note) |
|
*1: |
HD-PLC™: A registered trademark or trademark of Panasonic Corporation in Japan and other countries. |
*2: |
HD-PLC Alliance: Established on September 25, 2007 with the aim to expand the use of High-definition Power Line Communication (HD-PLC) and to ensure communication compatibility. |
*3: |
IEEE Standards Association: Standards association within the Institute of Electrical and Electronics Engineers (IEEE) |
IEEE 1901-2020 standard: https://standards.ieee.org/standard/1901-2020.html |
|
*4: |
IEEE SA and HD-PLC Alliance Webinar March 2021 |
|
Subtitle: Home networking, Industrial and Building automation through HD-PLC (High-Speed Powerline Communication) |
Learn more: https://standards.ieee.org/events/index.html |
|
*5: |
HD-PLC Alliance Homepage: https://hd-plc.org/ |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005273/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom